J B Chemicals & Pharmaceuticals Ltd
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]
- Market Cap ₹ 26,454 Cr.
- Current Price ₹ 1,702
- High / Low ₹ 2,030 / 1,371
- Stock P/E 43.3
- Book Value ₹ 207
- Dividend Yield 0.72 %
- ROCE 24.6 %
- ROE 20.0 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 33.7%
Cons
- Stock is trading at 8.23 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Healthcare BSE 250 SmallCap Index Nifty Smallcap 250 BSE Allcap BSE SmallCap Select Index
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
866 | 1,022 | 1,144 | 1,210 | 1,344 | 1,408 | 1,643 | 1,775 | 2,043 | 2,424 | 3,149 | 3,484 | 3,711 | |
760 | 874 | 964 | 1,004 | 1,112 | 1,191 | 1,337 | 1,397 | 1,482 | 1,881 | 2,454 | 2,587 | 2,739 | |
Operating Profit | 106 | 148 | 180 | 206 | 232 | 218 | 306 | 378 | 560 | 543 | 696 | 897 | 972 |
OPM % | 12% | 14% | 16% | 17% | 17% | 15% | 19% | 21% | 27% | 22% | 22% | 26% | 26% |
27 | -27 | 11 | 58 | 50 | 37 | 41 | 41 | 112 | 39 | 10 | 37 | 40 | |
Interest | 4 | 6 | 7 | 11 | 5 | 3 | 5 | 3 | 7 | 5 | 36 | 44 | 30 |
Depreciation | 25 | 28 | 39 | 41 | 47 | 57 | 56 | 66 | 69 | 73 | 114 | 138 | 157 |
Profit before tax | 104 | 87 | 146 | 212 | 230 | 194 | 287 | 349 | 597 | 505 | 555 | 752 | 825 |
Tax % | 23% | 30% | 31% | 23% | 20% | 28% | 32% | 22% | 25% | 24% | 26% | 26% | |
79 | 62 | 100 | 163 | 184 | 139 | 194 | 272 | 449 | 386 | 410 | 553 | 611 | |
EPS in Rs | 4.69 | 3.63 | 5.92 | 9.58 | 10.85 | 8.28 | 12.05 | 17.60 | 28.98 | 24.93 | 26.48 | 35.61 | 39.37 |
Dividend Payout % | 32% | 41% | 118% | 26% | 5% | 12% | 21% | 31% | 28% | 33% | 34% | 34% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 16% |
3 Years: | 19% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 20% |
5 Years: | 24% |
3 Years: | 10% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | 33% |
5 Years: | 54% |
3 Years: | 29% |
1 Year: | 13% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 20% |
3 Years: | 19% |
Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 15 | 15 | 15 | 15 | 16 | 16 |
Reserves | 1,003 | 1,026 | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 | 2,908 | 3,197 |
50 | 93 | 127 | 193 | 49 | 29 | 26 | 29 | 45 | 55 | 572 | 378 | 93 | |
230 | 215 | 365 | 270 | 262 | 294 | 286 | 349 | 376 | 412 | 495 | 687 | 724 | |
Total Liabilities | 1,300 | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,988 | 4,029 |
334 | 311 | 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,901 | 2,004 | 2,016 | |
CWIP | 5 | 46 | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 | 42 |
Investments | 398 | 500 | 552 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 388 | 345 |
563 | 494 | 552 | 594 | 580 | 674 | 699 | 743 | 894 | 1,293 | 1,385 | 1,519 | 1,627 | |
Total Assets | 1,300 | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,988 | 4,029 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
84 | -14 | 127 | 140 | 201 | 123 | 194 | 276 | 315 | 170 | 626 | 801 | |
-116 | -142 | -112 | -26 | -45 | -21 | -28 | 24 | -231 | 2 | -962 | -404 | |
-31 | 12 | -1 | -100 | -184 | -60 | -156 | -306 | -87 | -138 | 357 | -385 | |
Net Cash Flow | -63 | -144 | 13 | 15 | -28 | 43 | 11 | -6 | -3 | 34 | 20 | 11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 81 | 84 | 84 | 82 | 72 | 78 | 68 | 71 | 70 | 84 | 67 | 72 |
Inventory Days | 104 | 120 | 122 | 146 | 138 | 145 | 149 | 159 | 181 | 178 | 134 | 155 |
Days Payable | 60 | 54 | 63 | 71 | 68 | 75 | 72 | 97 | 97 | 97 | 75 | 110 |
Cash Conversion Cycle | 124 | 150 | 143 | 158 | 142 | 148 | 146 | 133 | 153 | 164 | 127 | 117 |
Working Capital Days | 80 | 99 | 56 | 96 | 88 | 101 | 97 | 87 | 99 | 127 | 102 | 91 |
ROCE % | 8% | 13% | 13% | 15% | 14% | 11% | 18% | 23% | 33% | 23% | 22% | 25% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
1d - Allotment of 95,300 equity shares under ESOP.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 Nov - Transcript of Q2 FY25 earnings call for JB Pharma.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
7 Nov - Audio recording of Q2 results investor call available.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 7 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Nov - Newspaper cutting of extract of consolidated financial results for quarter ended on September 30, 2024
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Dec 2023Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
Revenue Split H1FY24
Domestic Formulations - 55%
Export Formulations - 30%
Contract Manufacturing - 13%
APIs - 2% [1]